Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQ: CRVS · Real-Time Price · USD
14.08
-1.37 (-8.87%)
At close: Mar 18, 2026, 4:00 PM EDT
14.20
+0.12 (0.85%)
After-hours: Mar 18, 2026, 5:42 PM EDT
Corvus Pharmaceuticals Employees
Corvus Pharmaceuticals had 37 employees as of December 31, 2025. The number of employees increased by 6 or 19.35% compared to the previous year.
Employees
37
Change (1Y)
6
Growth (1Y)
19.35%
Revenue / Employee
n/a
Profits / Employee
-$413,054
Market Cap
1.18B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 37 | 6 | 19.35% | 37 | 0 |
| Dec 31, 2024 | 31 | 3 | 10.71% | 31 | 0 |
| Dec 31, 2023 | 28 | -1 | -3.45% | 28 | 0 |
| Dec 31, 2022 | 29 | 1 | 3.57% | 29 | 0 |
| Dec 31, 2021 | 28 | -14 | -33.33% | 28 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| EyePoint | 214 |
| Monte Rosa Therapeutics | 147 |
| Precigen | 143 |
| Olema Pharmaceuticals | 131 |
| MoonLake Immunotherapeutics | 130 |
| Septerna | 130 |
| Kodiak Sciences | 123 |
| ORIC Pharmaceuticals | 104 |
CRVS News
- 5 days ago - Corvus Pharmaceuticals, Inc. (CRVS) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 13 days ago - Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026 - GlobeNewsWire
- 23 days ago - Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 7 weeks ago - Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M - GlobeNewsWire
- 7 weeks ago - Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock - GlobeNewsWire
- 2 months ago - Corvus Pharmaceuticals: ITK Inhibitor Soquelitinib AD Data Could Be Improved Upon - Seeking Alpha
- 2 months ago - Soquelitinib Data Push Corvus Pharmaceuticals Stock Higher: What You Should Know - Seeking Alpha